This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Viatris, formerly Mylan, agrees to pay $264 million to resolve US antitrust claims over EpiPen

( February 28, 2022, 15:03 GMT | Official Statement) -- MLex Summary: Viatris, formerly Mylan, has agreed to pay $264 million to resolve indirect purchasers' claims accusing it of conspiring to delay the market entry of generic EpiPen. The company said in a statement it denies any allegation of wrongdoing to resolve the EpiPen Auto-Injector cases pending in US District Court for the District of Kansas. Viatris "maintains that it acted lawfully and pro-competitively and the settlement contains no admission of liability. The Company recorded an accrual of approximately $264.0 million related to this litigation in 2021," the statement said.See document below....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections